Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria

NCT02082860 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Intermittent Porphyria

Interventions

GENETIC: rAAV2/5-PBGD vector dosage 1
GENETIC: rAAV2/5-PBGD vector dosage 2
GENETIC: rAAV2/5-PBGD vector dosage 3
GENETIC: rAAV2/5-PBGD vector dosage 4

Sponsor

Digna Biotech S.L.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]